ABSTRACT
Objective To evaluate the effects of combined treatment for advanced epithelial ovarian carcinoma and to analyze its prognostic factors Methods Fifty three patients treated with a three step combined therapeutic regimen were defined as research arm The procedures of the three step combined treatment were as follows: induction of tumor remission, sequential chemotherapy and adjuvant immunotherapy Three hundred and eighteen patients with advanced epithelial ovarian carcinoma treated with cytoreductive surgery and systemic chemotherapy were retrospectively classified into control arm Results The rates of complete response and partial response in the research arm were significantly differed from those in the control arm (90 6%, 5 7% Vs 70 1%, 5 3%, P
ABSTRACT
Objective To assess the role of CA 125 monoclonal antibody in the differential diagnosis of primary ovarian carcinoma and metastatic ovarian carcinoma originated from the gastrointestinal tract Methods Immunohistochemical study using CA 125 monoclonal antibody was performed on 33 primary ovarian cancer and 50 metastatic ovarian cancer of gastrointestinal origin Results The positivity of CA 125 was 84 5% in 33 cases of primary ovarian carcinoma, while in 50 metastatic ovarian carcinoma cases, only 4 0% was CA 125 positive The positivity of CA 125 was significantly higher in primary ovarian carcinoma than metastatic ovarian carcinoma ( P
ABSTRACT
Objective To study the response rate and toxic side effect of Vindesine, aclarubicin and mitomycin (VAM) as a new regime of second line chemotherapy for ovarian carcinoma refractory to platinum group of drugs.Methods From June 1997 through August 1998, 25 cases of refractory ovarian carcinoma were treated with VAM regime. The response rate and the side reactions were analyzed. Results The overall response rate was 32.0%, with 3 complete response (CR) and 5 partial response (PR). In the platinum refractory, platinum-resistant platinum-senstitive strata, the response rates were 18.2% 28.6% and 57.1% respectively. Myelosuppression was the main toxic effect. Grade 3 and grade 4 neutropenia occurred in 40.0% and thrombocytopenia in 28.0% of the patients. Alopecia occurred in 32% of cases. Gastrointastinal, cardiac and neurologic toxicities were mild. Conclusion VAM regime is a practical and effective second-line chemotherapy for patients with ovarian carcinoma refractory to platinum based chemothrapy.
ABSTRACT
Purpose:In order to improve the survival rate of recurrent ovarian carcinoma, influencing factors and the effects of combined therapy of recurrent epithelial ovarian carcinoma were investigated. Methods:From January 1998 to December 2000,60 patients with recurrent epithelial ovarian carcinoma were enrolled in the present study as research arm. The procedures of the combined treatment were as follows: After second cytoreductive surgery, platinum sensitive patients were treated with TP regimen (taxol+DDP) or CC regimen (CBP+CTX) and platinum resistant patients used TM regimen(taxol+MMC) or VM regimen(VP 16+MMC). Chemotherapy with 2/3 doses was continued after disease remission. Pelvic radiotherapy was performed for those with pelvic residual disease. IFN and/or IL 2 were administrated during chemotherapy and radiotherapy. 167 patients with recurrent epithelial ovarian carcinoma from January 1986 to December 1997, were retrospectively classified as control arm in this study. The patients were mainly treated with combined chemotherapy (CAP regimen) and traditional Chinese medicine applied as adjuvant therapy. Results:The rates of CR and PR in the research arm differed significantly from that in the control arm (43.33%, 45.00% vs. 2.99%, 7.78% P = 0.000). The 1 , 2 and 3 year survival rates of the research arm and control arm were 89.38%, 79.69%, 71.25% vs. 64.58%, 40.39%, 31.20% respectively ( P
ABSTRACT
Purpose:In order to deterimine the role of CK7 and other monoclonal antibodies in identification of primary and metastatic malignant ascites due to ovarian carcinoma.Methods:We used immunocytochemical ABC assay to detect the experssions of CK7、MG7、CEA、AB、CK、CK8、EMA、HBME、LCA、VIM monoclonal antibodies in 43 ascitic samples and 22 specimens. Chi square was used for statistic assay with SPSS 8.0 software. Results:One way ANOV assay showed that: (1) Cytokeratin 7 monoclonal antibody can be a very useful mark of primary ovarian carcinoma. (2) MG7 expression in peritoneal cells was significantly different in primary ovarian cancer and metastatic ovarian carcinoma of gastric origin. (3) CEA can be helpful in suggesting the origin of intestine carcinoma or not. (4) Immunohistochemical study of the peritoneal fluids showed results, similar to those in specimens. Conclusions: Immunocytochemical assay in the peritoneal fluids is a helpful diagnostic modality in differentiating between primary and metastatic ascites due to ovarian carcinoma.